All articles by Janet Beal

VPAS is dead, long live VPAG—could the UK’s new clawback revision save the day?    

The new scheme for 2024–28, renamed the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), with details here, will be implemented in January.

The VPAS fallout continues – Celltrion pulls high-profile biosimilar from UK market

Celltrion is signalling that it might cease its UK operations altogether if the hostile financial climate does not improve.

Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs

The government’s unprecedented 26.5% payback rate on NHS sales of branded medicines this year is almost double that of 2022.

Ukraine’s healthcare system – resilience under fire

Ukraine’s health minister Viktor Lyashko pushes for ‘business as usual’ as Russia invades, but ingenuity and support are needed.

The UK’s first drug approval via Project Orbis – pulling away from the EMA strings?

UK bans parallel export of two COVID-19 treatment candidates to protect national supply

Zolgensma may be a potential game-changer for SMA

So, was this worth the wait?…the UK government finally responds to last year’s Accelerated Access Review

Time for a consultation on the impact of Brexit on the UK’s access to medicines: Better late than never?

Can Affordable Medicines become a reality for Ukraine?